Posted in | News

Integrated Project Services to Build New Drug Manufacturing Facility for Pharmalucence

Pharmalucence declared that it has chosen Integrated Project Services (IPS) to offer architectural design, technology and construction services for its proposed high-tech pharmaceutical manufacturing facility to be located in Billerica, MA.

Pharmalucence New facility

The privately held company resists the current trend of shifting the manufacturing facilities outside the USA by the proposal of building its aseptic production facility in Billerica, MA. The new facility will offer permanent employment opportunities to 25 to 30 people during the next two years.

Pharmalucence has already commenced the first phase of its building agenda to facilitate moving part of its operations to the new construction in the last part of 2011. The company is planning to complete all the construction phases of the building by the middle of 2012 to commence its full-fledged drug production in the middle of 2013. The construction project has received a partial grant for the construction under the Massachusetts Recovery Zone Facility Bond program provided on behalf of the company by Mass-Development.

According to Ed Connolly, Chief Operating Officer of Pharmalucence, the company is making the investment in the life sciences industry of Boston area to establish a modern manufacturing facility to produce its own products and the products of other clients. He added that the new construction will feature sophisticated aseptic technologies in association with IPS.

Source: http://www.pharmalucence.com

Joel Scanlon

Written by

Joel Scanlon

Joel relocated to Australia in 1995 from the United Kingdom and spent five years working in the mining industry as an exploration geotechnician. His role involved utilizing GIS mapping and CAD software. Upon transitioning to the North Coast of NSW, Australia, Joel embarked on a career as a graphic designer at a well-known consultancy firm. Subsequently, he established a successful web services business catering to companies across the eastern seaboard of Australia. It was during this time that he conceived and launched News-Medical.Net. Joel has been an integral part of AZoNetwork since its inception in 2000. Joel possesses a keen interest in exploring the boundaries of technology, comprehending its potential impact on society, and actively engaging with AI-driven solutions and advancements.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Scanlon, Joel. (2019, February 22). Integrated Project Services to Build New Drug Manufacturing Facility for Pharmalucence. AZoBuild. Retrieved on November 22, 2024 from https://www.azobuild.com/news.aspx?newsID=14172.

  • MLA

    Scanlon, Joel. "Integrated Project Services to Build New Drug Manufacturing Facility for Pharmalucence". AZoBuild. 22 November 2024. <https://www.azobuild.com/news.aspx?newsID=14172>.

  • Chicago

    Scanlon, Joel. "Integrated Project Services to Build New Drug Manufacturing Facility for Pharmalucence". AZoBuild. https://www.azobuild.com/news.aspx?newsID=14172. (accessed November 22, 2024).

  • Harvard

    Scanlon, Joel. 2019. Integrated Project Services to Build New Drug Manufacturing Facility for Pharmalucence. AZoBuild, viewed 22 November 2024, https://www.azobuild.com/news.aspx?newsID=14172.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.